Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$291K Sell
18,318
-1,500
-8% -$23.2K 0.04% 149
2026
Q1
$268K Buy
19,818
+5
+0% +$70 0.05% 153
2025
Q4
$247K Buy
19,813
+2
+0% +$22 0.04% 163
2025
Q3
$196K Sell
19,811
-1,000
-5% -$9.73K 0.04% 171
2025
Q2
$186K Hold
20,811
0.04% 174
2025
Q1
$181K Hold
20,811
0.04% 166
2024
Q4
$259K Hold
20,811
0.05% 143
2024
Q3
$242K Sell
20,811
-37
-0.2% -$427 0.05% 151
2024
Q2
$222K Hold
20,848
0.05% 150
2024
Q1
$249K Hold
20,848
0.06% 134
2023
Q4
$226K Hold
20,848
0.06% 141
2023
Q3
$206K Sell
20,848
-9
-0% -$94 0.06% 155
2023
Q2
$208K Sell
20,857
-6
-0% -$57 0.06% 143
2023
Q1
$232K Hold
20,863
0.07% 140
2022
Q4
$232K Sell
20,863
-165
-0.8% -$1.72K 0.07% 140
2022
Q3
$179K Buy
21,028
+7,500
+55% +$73.8K 0.06% 144
2022
Q2
$142K Hold
13,528
0.04% 151
2022
Q1
$147K Buy
13,528
+3,001
+29% +$39.5K 0.04% 164
2021
Q4
$142K Buy
10,527
+138
+1% +$1.84K 0.04% 171
2021
Q3
$141K Buy
+10,389
New +$147K 0.04% 167

Other funds holding VTRS

Essex LLC's VTRS Position: Q2 2026 in Review

Essex LLC reduced its Viatris (VTRS) stake by 7.6% in Q2 2026, selling an estimated $23.2K and leaving 18,318 shares worth $291K. The position accounts for 0.04% of the portfolio, ranked #149.

Essex LLC first reported a position in VTRS in Q3 2021 and has held it in 20 quarters since. 1,026 funds tracked by Wall St. Rank hold VTRS as of Q2 2026.

  • Essex LLC held 18,318 shares of Viatris worth $291K as of Q2 2026.
  • Essex LLC sold 1,500 Viatris shares in Q2 2026, an estimated $23.2K.
  • Viatris made up 0.04% of Essex LLC's portfolio in Q2 2026, its #149 holding.
  • Essex LLC first reported a position in Viatris in Q3 2021 and has held it in 20 quarters since.
  • 1,026 funds tracked by Wall St. Rank held Viatris as of Q2 2026.

Based on Essex LLC's 13F filing for Q2 2026, filed 24 Jul 2026.